UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 60

Sortiert nach

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Annals of oncology, 2013-11, Vol.24 (11), p.2786-2793

2013

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvante Systemtherapie beim Mammakarzinom

Gynäkologe (Berlin), 2012-06, Vol.45 (6), p.453-459

2012

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Annals of oncology, 2013-12, Vol.24 (12), p.2978-2984

2013

Link zum Volltext

Verfügbarkeit prüfen

Effective oral chemotherapy for breast cancer: pillars of strength

Annals of oncology, 2008-02, Vol.19 (2), p.212-222

2008

Link zum Volltext

Verfügbarkeit prüfen

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

Annals of oncology, 2014-01, Vol.25 (1), p.81-89

2014

Link zum Volltext

Verfügbarkeit prüfen

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

Breast cancer research and treatment, 2018-02, Vol.168 (1), p.179-187

2018

Link zum Volltext

Verfügbarkeit prüfen

Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study

Annals of oncology, 2007-04, Vol.18 (4), p.689-693

2007

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

Annals of oncology, 2013-09, Vol.24 (9), p.2316-2324

2013

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer—comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial

Annals of oncology, 2009-02, Vol.20 (2), p.258-264

2009

Link zum Volltext

Verfügbarkeit prüfen

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

Breast cancer research and treatment, 2017-12, Vol.166 (3), p.775-785

2017

Link zum Volltext

Verfügbarkeit prüfen

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab: a translational project in the neoadjuvant GeparQuinto trial

British journal of cancer, 2012-09, Vol.107 (6), p.956-960

2012

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer patients' expectations in respect of the physician–patient relationship and treatment management results of a survey of 617 patients

Annals of oncology, 2007-03, Vol.18 (3), p.479-484

2007

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

Annals of oncology, 2010-11, Vol.21 (11), p.2188-2194

2010

Link zum Volltext

Verfügbarkeit prüfen

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

British journal of cancer, 2006-06, Vol.94 (11), p.1615-1620

2006

Link zum Volltext

Verfügbarkeit prüfen

Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy

British journal of cancer, 2013-09, Vol.109 (6), p.1528-1536

2013

Link zum Volltext

Verfügbarkeit prüfen

The AURORA initiative for metastatic breast cancer

British journal of cancer, 2014-11, Vol.111 (10), p.1881-1887

2014

Link zum Volltext

Verfügbarkeit prüfen

CD44 variant exon epitopes in primary breast cancer and length of survival

The Lancet (British edition), 1995-03, Vol.345 (8950), p.615-619

1995

Link zum Volltext

Verfügbarkeit prüfen

Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study

Annals of oncology, 2008-10, Vol.19 (10), p.1698-1705

2008

Link zum Volltext

Verfügbarkeit prüfen

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

Breast cancer research and treatment, 2004-08, Vol.86 (3), p.197-206

2004

Link zum Volltext

Verfügbarkeit prüfen

Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)

Breast cancer research and treatment, 2011-02, Vol.126 (1), p.109-117

2011

Link zum Volltext

Verfügbarkeit prüfen

Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

Annals of oncology, 2008-02, Vol.19 (2), p.292-298

2008

Link zum Volltext

Verfügbarkeit prüfen

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

Annals of oncology, 2011-02, Vol.22 (2), p.301-306

2011

Link zum Volltext

Verfügbarkeit prüfen

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study

Annals of oncology, 2005-01, Vol.16 (1), p.56-63

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 60

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Zeitschrift / SerieOnkologie

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(59)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(55)
Life Sciences & Biomedicine
(54)
Science & Technology
(54)
Biological And Medical Sciences
(53)
Female
(53)
Medical Sciences
(52)
Oncology
(50)
Gynecology. Andrology. Obstetrics
(44)
Breast Cancer
(43)
Mammary Gland Diseases
(43)
Middle Aged
(40)
Adult
(37)
Pharmacology. Drug Treatments
(33)
Breast Neoplasms - Drug Therapy
(32)
Antineoplastic Agents
(29)
Aged
(28)
Breast Neoplasms - Pathology
(26)
Treatment Outcome
(22)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Neoadjuvante Systemtherapie beim Mammakarzinom

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Effective oral chemotherapy for breast cancer: pillars of strength

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer—comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab: a translational project in the neoadjuvant GeparQuinto trial

Breast cancer patients' expectations in respect of the physician–patient relationship and treatment management results of a survey of 617 patients

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy

The AURORA initiative for metastatic breast cancer

CD44 variant exon epitopes in primary breast cancer and length of survival

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel±darbepoetin alfa in primary breast cancer—results at the time of surgery

Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)

Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study

Aktive Filter

Suchergebnisse filtern